Gilead Sciences Inc (GILDm)

Currency in ARS
50,650.000
-1,000.000(-1.94%)
Closed·
GILDm is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
50,650.00051,275.000
52 wk Range
27,675.00058,100.000
Key Statistics
Bid/Ask
50,700.00 / 55,500.00
Prev. Close
51,650
Open
50,950
Day's Range
50,650-51,275
52 wk Range
27,675-58,100
Volume
354
Average Vol. (3m)
540
1-Year Change
54.4207%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GILDm Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

Gilead Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Employees
17000
Market
Argentina

Compare GILDm to Peers and Sector

Metrics to compare
GILDm
Peers
Sector
Relationship
P/E Ratio
20.5x17.7x−0.5x
PEG Ratio
0.010.240.00
Price / Book
7.7x5.0x2.6x
Price / LTM Sales
5.9x3.4x3.2x
Upside (Analyst Target)
-13.4%45.7%
Fair Value Upside
Unlock14.4%4.8%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.78%
Dividend Yield
1.43%
Industry Median 2.23%
Annualized Payout
725.45
Paid quarterly
5-Years Growth
+3.04%
Growth Streak

Earnings

Latest Release
Feb 10, 2026
EPS / Forecast
1.74 / --
Revenue / Forecast
7.93B / --
EPS Revisions
Last 90 days

GILDm Income Statement

People Also Watch

57,725.00
BHPm
-0.69%
22,980.00
MAm
+0.79%
132,275.00
MUm
-2.54%
15,370.00
HDm
-2.04%
23,470.00
LLYm
-3.10%

FAQ

What Is the Gilead Sciences (GILDm) Stock Price Today?

The Gilead Sciences stock price today is 50,650.000 ARS.

What Stock Exchange Does Gilead Sciences Trade On?

Gilead Sciences is listed and trades on the Buenos Aires Stock Exchange.

What Is the Stock Symbol for Gilead Sciences?

The stock symbol for Gilead Sciences is "GILDm."

Does Gilead Sciences Pay Dividends? What’s The Current Dividend Yield?

The Gilead Sciences dividend yield is 1.43%.

What Is the Gilead Sciences Market Cap?

As of today, Gilead Sciences market cap is 235.900T ARS.

What Is Gilead Sciences's Earnings Per Share (TTM)?

The Gilead Sciences EPS (TTM) is 6.780.

From a Technical Analysis Perspective, Is GILDm a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Gilead Sciences Stock Split?

Gilead Sciences has split 0 times.

How Many Employees Does Gilead Sciences Have?

Gilead Sciences has 17000 employees.

What is the current trading status of Gilead Sciences (GILDm)?

As of Apr 16, 2026, Gilead Sciences (GILDm) is trading at a price of 50,650.000 ARS, with a previous close of 51,650.000 ARS. The stock has fluctuated within a day range of 50,650.000 ARS to 51,275.000 ARS, while its 52-week range spans from 27,675.000 ARS to 58,100.000 ARS.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.